PEPE has risen about 5% in the last 24 hours, trading above $0.000004 as meme coin market activity picks up. Despite this rebound, nearly $269 million in outstanding futures positions raise concerns about potential volatility and price reversals. The token faces resistance near $0.00000411, with further upside targets at $0.0000043 and $0.00000445 if it breaks through. The sustainability of this rally depends on stronger spot demand rather than leveraged futures speculation, as past recoveries have shown mixed momentum and large-holder buying has not guaranteed price gains.
PEPE price action is the subject, with nearly $269 million in futures positions open. For readers following cryptocurrency broadly, here is Pluang's market snapshot as of Oct 19, 2026 19:21 WIB: Among 50 major cryptocurrencies, 23 rose and 25 fell. Notable movers include ONE at Rp25 with a 3.61% decline and 52% sell order activity, BAT at Rp3,260 with a 3.12% gain and 93% buy order activity, and SAND at Rp1,058 with a 2.80% decline and 65% buy order activity.
Nyxoah announced preliminary Q3 2026 revenue of €9.2 million, up 19% sequentially, driven by a 29% increase in U.S. sales. The company submitted a PMA supplement to the FDA to expand its Genio device indication for patients with complete concentric c...
ASML Holding N.V. announced recent transactions under its ongoing share buyback program, repurchasing a total of 233,867 shares between October 12 and October 16, 2026. The shares were bought back at weighted average prices ranging from €1,444.83 to ...
The Phase 3 ALKIVIA trial demonstrated that efgartigimod significantly improves symptoms in patients with autoimmune myositis, including immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM). Patients showed meaningful clinical improve...
In 2025, Berkshire Hathaway, led by Greg Abel, received $479 million in dividends from its $1.3 billion investment in American Express. This highlights the value of holding strong dividend-paying stocks for steady income. Retail investors can apply s...
Lexeo Therapeutics announced an educational event on October 21, 2026, focusing on clinical endpoints and outcome measures in PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM). The event will feature discussions by Lexeo's Chief Medical Officer and a lea...
